Company / SG&A Expense
Black Diamond Therapeutics, Inc. SG&A Expense History
FY2019-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$21.4M
FY2020
5-year range
$7.6M / $21.4M
FY2019-FY2020
Trend
+181.8%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$21M in FY2020.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, sg&a expense increased 181.8% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.60 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $21.4M | +181.8% |
| FY2019 | $7.6M | - |
As of FY2020 · SEC Form 10-K · Last checked Jun 21, 2026